Prodrug Integrated Envelope on Probiotics to Enhance Target Therapy for Ulcerative Colitis
Advanced Science · 2023-02 · 10 (4)
DOI: 10.1002/advs.202205422 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 11.12.2022. Verfasst von Kun Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Prodrugs, Probiotics. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Funds for the National Key R&D Project, National Natural Science Foundation of China, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Ulcerative colitis (UC), affecting millions of patients worldwide, is associated with disorders of the gut microbiota. Probiotics‐based therapy positively regulating the community structure of gut microbiota is regarded as an efficient intervention for UC. However, oral probiotics delivery is restricted by limited bioactivity, short retention time, complex pathological condition, and single therapeutic efficacy. Here, a bioengineered probiotic decorated with a multifunctional prodrug coating is constructed to ameliorate the aforementioned shortcomings. The results of UC mice induced by dextran sulfate sodium demonstrate that the intrinsic features of the fabricated coating integrate gut microbes protection, colon‐targeted drug release, prolonged drug retention, and inflammation regulation. In parallel, the probiotics Lactobacillus rhamnosus GG (LGG) could regulate the composition of the gut microbiota and improve epithelial barrier function, thereby synergistically ameliorating UC. These results provide ample shreds of evidence of the therapeutic effect on UC, therefore, demonstrate a great promise as the potential therapeutic strategy for UC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Chongqing, 400030, P…
- Chongqing University Three Gorges Hospital, Chongqing Municipality Clinical Research Center for Geriatric diseases, Chongqing, 404000, P. R. China.
- Institute of Life Sciences and Biomedical Collaborative Innovation Center of Zhejiang Province, Wenzhou University, Wenzhou, Zhejiang, 325035, P. R. China.
- Jin Feng Laboratory, Chongqing, 401329, P. R. China.
ORCID-Profile: Wei Wu
Förderung
- Fundamental Research Funds for the National Key R&D Project
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Natural Science Foundation of Chongqing
- Jin Feng Laboratory of Chongqing
- Fundamental Research Funds for Central Universities
Zitieren
APA
Zhang, K., Zhu, L., Zhong, Y., Xu, L., Lang, C., Chen, J., Yan, F., Li, J., Qiu, J., Chen, Y., Sun, D., Wang, G., Qu, K., Qin, X., & Wu, W. (2023). Prodrug Integrated Envelope on Probiotics to Enhance Target Therapy for Ulcerative Colitis. Advanced Science, 10(4). https://doi.org/10.1002/advs.202205422
Vancouver
Zhang K, Zhu L, Zhong Y, Xu L, Lang C, Chen J, et al. Prodrug Integrated Envelope on Probiotics to Enhance Target Therapy for Ulcerative Colitis. Advanced Science. 2023;10(4). doi:10.1002/advs.202205422
BibTeX
@article{Zhang2023,
author = {Zhang, Kun and Zhu, Li and Zhong, Yuan and Xu, Lixin and Lang, Chunhui and Chen, Jian and Yan, Fei and Li, Jiawei and Qiu, Juhui and Chen, Yidan and Sun, Da and Wang, Guixue and Qu, Kai and Qin, Xian and Wu, Wei},
title = {Prodrug Integrated Envelope on Probiotics to Enhance Target Therapy for Ulcerative Colitis},
journal = {Advanced Science},
year = {2023},
volume = {10},
number = {4},
doi = {10.1002/advs.202205422}
}
EUVIMED